Expression and functional characterization of an anti-CD22 scFv targeting B-cell malignancies
This study established a scalable and cost-effective strategy for producing functional CD22-scFv with high specificity and anti-proliferative effects. The findings highlight its potential for targeted therapies and diagnostics, warranting further <i>in vivo</i> and clinical studies.
Authors
- Arash Arashkia (ORCID: https://orcid.org/0000-0002-3117-3217)
- Farhad Riazi‐Rad (ORCID: https://orcid.org/0000-0002-5114-4173)
- Zahra Sharifzadeh (ORCID: https://orcid.org/0000-0002-4419-0315)
- Shafieeh Mansoori (ORCID: https://orcid.org/0000-0003-0260-2497)
- Shahriyar Abdoli (ORCID: https://orcid.org/0000-0002-4052-332X)
- Amir Ali Hamidieh
- Mohammad Nouri
- Monireh Gholizadeh (ORCID: https://orcid.org/0000-0003-3851-1503)
Institutions
- Pasteur Institute of Iran (IR)
- Tabriz University of Medical Sciences (IR)
- Golestan University (IR)
- Golestan University of Medical Sciences (IR)
- Stem Cell Technology Research Center (IR)
- Tehran University of Medical Sciences (IR)
Publication Details
- Journal
- Research in Pharmaceutical Sciences
- Published
- 2025-05-01
- DOI
- https://doi.org/10.4103/rps.rps_248_24
- Citations
- 2
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 2.72